API | zanolimumab

zanolimumab Report issue

Biologics mAb Experimental

AACT ChEMBL

Active Ingredient History

NOW

Zanolimumab is an investigational human monoclonal antibody and an immunosuppressive drug. It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma. Development of the drug was ultimately discontinued with termination of all trials. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

zanolimumab

mdx-cd4

More Chemistry

Pharmacology

Mechanisms of Action:
- T-cell surface glycoprotein CD4 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

humax-cd4 | mdx-016 | mdx-cd4 | zanolimumab

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)

Arthritis, Rheumatoid (Phase 2/Phase 3)

Lymphoma, T-Cell (Phase 2/Phase 3)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Melanoma (Phase 2)

Mycosis Fungoides (Phase 3)

Neoplasm Metastasis (Phase 2)

Sezary Syndrome (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue